Rituximab in Autoimmune CNS Disease

J Gordon Millichap; John J Millichap

doi:10.15844/pedneurbriefs-28-8-7

Rituximab in Autoimmune CNS Disease

Pediatric Neurology Briefs

Volume 28 (2014): Issue 8

By: J Gordon Millichap and John J Millichap

Open Access

|Aug 2014

Abstract

Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS.

References

Dale RC Brilot F Duffy LV Twilt M Waldman AT Narula S Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease Neurology 2014 Jul 8 83 2 142 50 10.1212/WNL.0000000000000570 24920861
Open DOI Search in Google Scholar Back to article
Chitnis T Waubant E B-cell depletion in children with neuroimmunologic conditions: the learning curve Neurology 2014 Jul 8 83 2 111 2 10.1212/WNL.0000000000000576 24920852
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-28-8-7 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 62 - 62

Published on: Aug 1, 2014

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Opsoclonus,

Rankin Scale,

Rituximab

© 2014 J Gordon Millichap, John J Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 28 (2014): Issue 8